EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study (2022–23)

Gabriele Bianco iD, Matteo Boattini iD, Laura Lupo, Simone Ambretti, Rita Greco, Linda Degl'Innocenti, Sofia Chiatamone Ranieri, Teresa Fasciana, Annarita Mazzariol iD, Davide Gibellini, Guido Antonelli, Federica Sacco und 9 weitere

Journal of Antimicrobial Chemotherapy · 03.02.2025 · 80 (2) · 583-592

DOI: 10.1093/jac/dkae450 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 19.12.2024. Verfasst von Gabriele Bianco und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, University of Salento, Lecce, Italy. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Anti-Bacterial Agents, beta-Lactamases, Klebsiella Infections. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the in vitro activity of ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae (KPC-Kp) clinical isolates collected from a multicentre study in Italy (2022–23) and genomic characterization of the molecular mechanisms causing resistance.

Methods

Consecutive KPC-Kp isolates from blood cultures (n = 264) were collected from 14 hospital centres in the period 2022–23. Antimicrobial susceptibility testing was performed using broth microdilution. WGS was used to investigate KPC-Kp strains resistant to the new approved β-lactam/β-lactam inhibitor combinations (BLICs).

Results

Overall, meropenem/vaborbactam (95.1% susceptible by EUCAST and 93.9% susceptible by CLSI; MIC50 = 0.5 mg/L; MIC90 = 4 mg/L) and imipenem/relebactam (97% susceptible by EUCAST and 92.8% susceptible by CLSI; MIC50 = 0.25 mg/L; MIC90 = 0.5 mg/L) showed similar activity, followed by ceftazidime/avibactam (93.9% susceptible by both EUCAST and CLSI; MIC50 = 2 mg/L; MIC90 = 8 mg/L). Ten out of 13 (76.9%) KPC-Kp resistant to ceftazidime/avibactam carried a blaKPC variant including blaKPC-31, blaKPC-205, blaKPC-203 and blaKPC-93. Among KPC-Kp resistant to meropenem/vaborbactam and imipenem/relebactam, 90.9% (10/11) and 80% (4/5) harboured a WT carbapenemase (i.e. blaKPC-2 or blaKPC-3), respectively. All strains resistant to meropenem/vaborbactam and/or imipenem/relebactam carried truncated OmpK35 and/or mutated (ins135GD) OmpK36.

Conclusions

New BLICs were shown to be the most widely active therapeutic option against KPC-Kp clinical isolates collected in Italy. Ceftazidime/avibactam resistance is mainly driven by the expression of KPC variants, whereas the loss of function of the OmpK35 and OmpK36 porins appears to play a key but not exclusive role in the development of meropenem/vaborbactam and/or imipenem/relebactam resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaeAnti-Bacterial Agentsbeta-LactamasesKlebsiella InfectionsDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsItalyAzabicyclo CompoundsCeftazidimeDrug CombinationsImipenemMeropenemBacterial Proteinsbeta-Lactamase InhibitorsBoronic AcidsWhole Genome SequencingHeterocyclic Compounds, 1-Ring

Substanzen

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimebeta-LactamasesDrug CombinationsImipenemMeropenemavibactam, ceftazidime drug combinationrelebactammeropenem and vaborbactam

Autor:innen und Institutionen

  • Department of Experimental Medicine, University of Salento, Lecce, Italy.
  • Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy.
  • Department of Public Health and Paediatrics, University of Torino, Turin, Italy.
  • Lisbon Academic Medical Centre, Lisbon, Portugal.
  • Clinical Pathology and Microbiology Unit, Vito Fazzi Hospital, Lecce, Italy.
  • Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, Bologna 40138, Italy.

ORCID-Profile: Gabriele Bianco, Matteo Boattini, Annarita Mazzariol, Paolo Gaibani

Zitieren

APA

Bianco, G., Boattini, M., Lupo, L., Ambretti, S., Greco, R., Degl'Innocenti, L., Chiatamone Ranieri, S., Fasciana, T., Mazzariol, A., Gibellini, D., Antonelli, G., Sacco, F., Quirino, A., Farina, C., Paglietti, B., Comini, S., Fiamma, M., Broccolo, F., Cavallo, R., …, & Gaibani, P. (2025). In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study (2022–23). Journal of Antimicrobial Chemotherapy, 80(2), 583-592. https://doi.org/10.1093/jac/dkae450

Vancouver

Bianco G, Boattini M, Lupo L, Ambretti S, Greco R, Degl'Innocenti L, et al. In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study (2022–23). Journal of Antimicrobial Chemotherapy. 2025;80(2):583-592. doi:10.1093/jac/dkae450

BibTeX
@article{Bianco2025,
  author = {Bianco, Gabriele and Boattini, Matteo and Lupo, Laura and Ambretti, Simone and Greco, Rita and Degl'Innocenti, Linda and Chiatamone Ranieri, Sofia and Fasciana, Teresa and Mazzariol, Annarita and Gibellini, Davide and Antonelli, Guido and Sacco, Federica and Quirino, Angela and Farina, Claudio and Paglietti, Bianca and Comini, Sara and Fiamma, Maura and Broccolo, Francesco and Cavallo, Rossana and Costa, Cristina and Gaibani, Paolo},
  title = {In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study (2022–23)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {2},
  pages = {583--592},
  doi = {10.1093/jac/dkae450}
}
Kostenlos starten →